edaravone has been researched along with Neurodegenerative Diseases in 8 studies
Neurodegenerative Diseases: Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone, is a free-radical scavenger, it has been shown to inhibit motor neuron death in animal models by reducing oxidative stress & it has shown efficacy in a small subset of people with ALS." | 5.72 | Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population. ( Gupta, S; Singal, A; Soni, R; Tomar, S, 2022) |
| "Sepsis is a major clinical challenge and septic encephalopathy is its nasty complication." | 5.38 | Neurodegenerative evidence in mice brains with cecal ligation and puncture-induced sepsis: preventive effect of the free radical scavenger edaravone. ( Chiba, S; Hattori, Y; Sagara, H; Takano, Y; Takashina, M; Tomita, K; Yagisita, S; Yokoo, H, 2012) |
| "Edaravone has been shown to reduce oxidative stress, edema, infarct volume, inflammation and apoptosis following ischemic injury of the brain in the adult as well as decrease free radical production in the neonatal brain following hypoxic-ischemic insult." | 2.44 | Antioxidants and neuroprotection in the adult and developing central nervous system. ( Kaur, C; Ling, EA, 2008) |
| "Edaravone, is a free-radical scavenger, it has been shown to inhibit motor neuron death in animal models by reducing oxidative stress & it has shown efficacy in a small subset of people with ALS." | 1.72 | Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population. ( Gupta, S; Singal, A; Soni, R; Tomar, S, 2022) |
| "EDA is a molecule approved for the treatment of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease associated with an increase of QUIN concentrations in both serum and cerebrospinal fluid." | 1.72 | Chromatographic measurement of 3-hydroxyanthranilate 3,4-dioxygenase activity reveals that edaravone can mitigate the formation of quinolinic acid through a direct enzyme inhibition. ( Altomare, A; Mercolini, L; Mondanelli, G; Protti, M; Regazzoni, L; Sanz, I; Valsecchi, V; Volpi, C, 2022) |
| "Sepsis is a major clinical challenge and septic encephalopathy is its nasty complication." | 1.38 | Neurodegenerative evidence in mice brains with cecal ligation and puncture-induced sepsis: preventive effect of the free radical scavenger edaravone. ( Chiba, S; Hattori, Y; Sagara, H; Takano, Y; Takashina, M; Tomita, K; Yagisita, S; Yokoo, H, 2012) |
| "Edaravone (Eda) is a potent scavenger of hydroxyl radicals and has been demonstrated to be beneficial for patients with acute ischemic stroke." | 1.35 | Edaravone protects against MPP+ -induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway. ( Chen, H; Ding, JH; Hu, G; Wang, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tomar, S | 1 |
| Gupta, S | 1 |
| Singal, A | 1 |
| Soni, R | 1 |
| Park, JM | 1 |
| Park, D | 1 |
| Kim, HJ | 1 |
| Park, JS | 1 |
| Sanz, I | 1 |
| Altomare, A | 1 |
| Mondanelli, G | 1 |
| Protti, M | 1 |
| Valsecchi, V | 1 |
| Mercolini, L | 1 |
| Volpi, C | 1 |
| Regazzoni, L | 1 |
| Oosthoek, M | 1 |
| Lili, A | 1 |
| Almeida, A | 1 |
| van Loosbroek, O | 1 |
| van der Geest, R | 1 |
| de Greef-van der Sandt, I | 1 |
| van Bokhoven, P | 1 |
| Sikkes, SAM | 1 |
| Teunissen, CE | 1 |
| Vijverberg, EGB | 1 |
| Chen, H | 1 |
| Wang, S | 1 |
| Ding, JH | 1 |
| Hu, G | 1 |
| Kaur, C | 1 |
| Ling, EA | 1 |
| Yoneyama, M | 1 |
| Shiba, T | 1 |
| Ogita, K | 1 |
| Yokoo, H | 1 |
| Chiba, S | 1 |
| Tomita, K | 1 |
| Takashina, M | 1 |
| Sagara, H | 1 |
| Yagisita, S | 1 |
| Takano, Y | 1 |
| Hattori, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label,Crossover,Pilot Study to Assess the Efficacy & Safety of Perispinal Admin.of Etanercept(Enbrel®) in Comb.w/Nutritional Supplements vs. Nutritional Supplements Alone in Subj. w/Mild to Mod. Alzheimer's Disease Receiving Std. Care.[NCT01716637] | Phase 1 | 12 participants (Anticipated) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for edaravone and Neurodegenerative Diseases
| Article | Year |
|---|---|
Antioxidants and neuroprotection in the adult and developing central nervous system.
Topics: Animals; Antioxidants; Antipyrine; Apoptosis; Central Nervous System; Edaravone; Free Radical Scaven | 2008 |
[Stimulative effect of edaravone on growth of neuronal stem cells and precursor cells following lesioning of hippocampal dentate gyrus].
Topics: Animals; Antipyrine; Cells, Cultured; Dentate Gyrus; Edaravone; Free Radical Scavengers; Hippocampus | 2011 |
1 trial available for edaravone and Neurodegenerative Diseases
| Article | Year |
|---|---|
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease Patients.
Topics: Alzheimer Disease; Biomarkers; Edaravone; Humans; Neurodegenerative Diseases; Randomized Controlled | 2023 |
5 other studies available for edaravone and Neurodegenerative Diseases
| Article | Year |
|---|---|
Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis Patients in Indian Population.
Topics: Amyotrophic Lateral Sclerosis; Animals; Antipyrine; Double-Blind Method; Edaravone; Humans; Neurodeg | 2022 |
Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.
Topics: Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Humans; Neurodegenerative | 2022 |
Chromatographic measurement of 3-hydroxyanthranilate 3,4-dioxygenase activity reveals that edaravone can mitigate the formation of quinolinic acid through a direct enzyme inhibition.
Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; 3-Hydroxyanthranilic Acid; Amyotrophic Lateral Sclerosis; Eda | 2022 |
Edaravone protects against MPP+ -induced cytotoxicity in rat primary cultured astrocytes via inhibition of mitochondrial apoptotic pathway.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Animals, Newborn; Antipyrine; Apoptosis; Astrocytes; Brain; Ce | 2008 |
Neurodegenerative evidence in mice brains with cecal ligation and puncture-induced sepsis: preventive effect of the free radical scavenger edaravone.
Topics: Animals; Antipyrine; Blood-Brain Barrier; Cecum; Cytokines; Edaravone; Evans Blue; Fluorescein; Free | 2012 |